BC Week In Review | Jun 29, 2018
Clinical News

Arsanis discontinues Phase II of lead anti-infective

Arsanis Inc. (NASDAQ:ASNS) discontinued a double-blind, international Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. In...
BC Extra | Jun 28, 2018
Clinical News

Arsanis discontinues Phase II of lead anti-infective, shares plummet

Arsanis Inc. (NASDAQ:ASNS) discontinued a Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. The company's shares...
BC Week In Review | Nov 17, 2017
Financial News

Arsanis raises $60M IPO and private placement

On Nov. 15, Arsanis Inc. (NASDAQ:ASNS) raised $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through the sale of 4 million shares in the IPO underwritten...
BC Extra | Nov 16, 2017
Financial News

Arsanis rises on $60M IPO and private placement

Arsanis Inc. (NASDAQ:ASNS) jumped $4.03 (40%) to $14.03 on its first day of trading Thursday after raising $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through...
BC Extra | Apr 26, 2017
Financial News

Gates Foundation leads Arsanis' $45.5M series D

Infectious disease company Arsanis Inc. (Waltham, Mass.) raised $45.5 million in a series D round led by the Bill & Melinda Gates Foundation (Seattle. Wash.), a new investor. Also participating were new investors GV and...
BC Week In Review | Feb 10, 2017
Clinical News

ASN100: Ph II started

Arsanis began a double-blind, placebo-controlled, international Phase II trial to evaluate a single dose of IV ASN100 in about 350 high-risk, mechanically ventilated patients. ASN100 was discovered under a deal with Adimab, which is using...
BC Innovations | Feb 12, 2015
Targets & Mechanisms

High five for Arsanis

Researchers at Arsanis Inc. and Adimab LLC have identified an antibody that simultaneously neutralizes five Staphylococcus aureus toxins - defying the odds of hitting such diverse structures by fishing out an exposed conserved patch. While Arsanis...
BC Innovations | Sep 29, 2011
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Staphylococcus Panton-Valentine leukocidin (LukS-PV; pv); Panton-Valentine leukocidin chain F precursor (LukF-PV) Mouse and rabbit studies identified antibodies to leukocidin that could help treat Staphylococcus...
BC Innovations | Apr 1, 2010
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Rabbit model of Staphylococcus aureus-induced necrotizing pneumonia A rabbit model of necrotizing pneumonia could help identify new therapies for staphylococcal pneumonia. Community-associated methicillin-resistant S. aureus...
BC Week In Review | Aug 10, 2009
Company News

Nabi, GlaxoSmithKline deal

GlaxoSmithKline will acquire Nabi's PentaStaph pentavalent Staphylococcus aureus vaccine program and related assets for $20 million up front and $26 million in milestones. PentaStaph is a preclinical vaccine that contains capsular polysaccharides from S. aureus...
Items per page:
1 - 10 of 12